Nkarta
NKTX
Market cap $282M

4.00 USD

-0.34

7.83%

At close Oct 17, 4:00 PM EDT

Pre-market

4.06

+0.06

1.50%

1 day

-7.83%

5 days

7.82%

1 month

-25.79%

3 months

-47.16%

6 months

-49.11%

Year to date

-37.21%

1 year

27.39%

5 years

-91.65%

About: Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Employees: 150

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

215% more call options, than puts

Call options by funds: $1.51M | Put options by funds: $479K

189% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 18

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

7% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 27

2% less funds holding

Funds holding: 113 [Q1] → 111 (-2) [Q2]

35.01% less ownership

Funds ownership: 128.98% [Q1] → 93.97% (-35.01%) [Q2]

43% less capital invested

Capital invested by funds: $689M [Q1] → $391M (-$297M) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$13

225%

upside

Avg. target

$18.50

363%

upside

High target

$23

475%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Emily Bodnar 30% 1-year accuracy 34 / 112 met price target	450%upside $22	Buy Maintained	15 Aug 2024
Needham Gil Blum 40% 1-year accuracy 51 / 129 met price target	225%upside $13	Buy Reiterated	14 Aug 2024
Raymond James Laura Prendergast 67% 1-year accuracy 2 / 3 met price target	300%upside $16	Strong Buy Upgraded	14 Aug 2024
HC Wainwright & Co. Emily Bodnar 30% 1-year accuracy 34 / 112 met price target	475%upside $23	Buy Reiterated	24 Jul 2024

See Analyst Rankings

Financial journalist opinion

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

Nkarta to Participate in Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:

Nkarta to Participate in Upcoming Investor Conference

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Nkarta, Inc. data from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory large B-cell lymphoma, expected by end of 2024. The global non-Hodgkin's Lymphoma Therapeutics market is expected to grow to $17.5 billion by 2032. NKX019 has a better shot at being effective towards autoimmune disorders, because of several factors like no antigen escape, lower cell burden to go after and no tumor microenvironment.

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

The Motley Fool

Why Nkarta Stock Is Soaring Today

Raymond James upgraded Nkarta stock from outperform to a strong buy. The investment firm likes the biopharma's cash position and the opportunities for its lead candidate NKX019.

Why Nkarta Stock Is Soaring Today

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three doses of NKX019 on Days 0, 7, and 14.

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2024.

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that researchers at Columbia University Irving Medical Center (CUIMC) have initiated an investigator-sponsored trial (“IST”) of NKX019, Nkarta's allogeneic, CD19-directed chimeric antigen receptor (CAR) NK-cell therapy in patients with systemic lupus erythematosus (SLE). The IST broadens the clinical evaluation of NKX019 in lupus. In June 2024, Nkarta announced the initiation of Ntrust-1, its Phase 1 clinical trial of NKX019 in patients with lupus nephritis (LN).

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings.

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Zacks Investment Research

Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know

Nkarta (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know

3 Undervalued Stocks Primed for a 2X Return

For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan.

3 Undervalued Stocks Primed for a 2X Return

See News Rankings

Charts implemented using Lightweight Charts™